Loading
Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib lengthened survival and reduced the skin cancers caused by BRAF inhibition alone in metastatic BRAF-mutant melanoma, establishing dual blockade as the standard for targeted therapy.
Phase 3 double-blind trial of 423 patients with untreated BRAF V600E or V600K metastatic melanoma randomised to dabrafenib plus trametinib or dabrafenib plus placebo.
Median overall survival was 25.1 versus 18.7 months (hazard ratio 0.71), median progression-free survival 11.0 versus 8.8 months and response 69 versus 53 percent; cutaneous squamous cell carcinomas were fewer with the combination, while pyrexia was more common.
BRAF plus MEK inhibitor doublets replaced BRAF monotherapy, and dabrafenib-trametinib became the reference regimen for BRAF-mutant melanoma, later extended to adjuvant use in COMBI-AD.
Shares Dabrafenib, Trametinib, BRAF V600-mutant melanoma.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib, BRAF V600-mutant melanoma.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.